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Abstract
Background: Several interventions have been put in place to promote access to quality malaria case management
services in Uganda’s private sector, where most people seek treatment. This paper describes evidence using a mixedmethod approach to examine the role, readiness and performance of private providers at a national level in Uganda.
These data will be useful to inform strategies and policies for improving malaria case management in the private sector.
Methods: The ACTwatch national anti-malarial outlet survey was conducted concurrently with a fever case management study. The ACTwatch nationally representative anti-malarial outlet survey was conducted in Uganda between
May 18th 2015 and July 2nd 2015. A representative sample of sub-counties was selected in 14 urban and 13 rural
clusters with probability proportional to size and a census approach was used to identify outlets. Outlets eligible for
the survey met at least one of three criteria: (1) one or more anti-malarials were in stock on the day of the survey;
(2) one or more anti-malarials were in stock in the 3 months preceding the survey; and/or (3) malaria blood testing
(microscopy or RDT) was available. The fever case management study included observations of provider-patient
interactions and patient exit interviews. Data were collected between May 20th and August 3rd, 2015. The fever case
management study was implemented in the private sector. Potential outlets were identified during the main outlet
survey and included in this sub-sample if they had both artemisinin-based combination therapy (ACT) [artemether–
lumefantrine (AL)], in stock on the day of survey as well as diagnostic testing available.
Results: A total of 9438 outlets were screened for eligibility in the ACTwatch outlet survey and 4328 outlets were
found to be stocking anti-malarials and were interviewed. A total of 9330 patients were screened for the fever case
management study and 1273 had a complete patient observation and exit interview. Results from the outlet survey
illustrate that the majority of anti-malarials were distributed through the private sector (54.3%), with 31.4% of all
anti-malarials distributed through drug stores and 14.4% through private for-profit health facilities. Availability of different anti-malarials and diagnostic testing in the private sector was: ACT (80.7%), quality-assured (QA) ACT (72.0%),
sulfadoxine–pyrimethamine (SP) (47.1%), quinine (73.2%) and any malaria blood testing (32.9%). Adult QAACT ($1.62)
was three times more expensive than SP ($0.48). The results from the fever case management study found 44.4% of
respondents received a malaria test, and among those who tested positive for malaria, 60.0% received an ACT, 48.5%
received QAACT; 14.4% a non-artemisinin therapy; 14.9% artemether injection, and 42.5% received an antibiotic.
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Conclusion: The private sector plays an important role in malaria case management in Uganda. While several private
sector initiatives have improved availability of QAACT, there are gaps in malaria diagnosis and distribution of non-artemisinin monotherapies persists. Further private sector strategies, including those focusing on drug stores, are needed
to increase coverage of parasitological testing and removal of non-artemisinin therapies from the marketplace.
Keywords: Private sector, Case management, Anti-malarial, ACT, Diagnostics, RDT

Background
The private sector is an important provider of health
services in Uganda, with up to 80% of patients seeking
treatment from this sector [1, 2]. Private health facilities
in Uganda have included private for-profit hospitals and
clinics, pharmacies and drug stores—the latter which can
be licensed and unlicensed private sector outlets [3]. In
particular, drug stores, which constitute a large proportion of Uganda’s private sector have been found to be
one of the first points of care with an estimated 50% of
all anti-malarials distributed through these outlets [2, 4].
Since 2004, the Ugandan anti-malarial treatment policy
has stipulated the use of artemisinin-based combination therapy (ACT) for uncomplicated malaria. Prior to
2010, these treatment guidelines advocated for presumptive treatment of all suspected malaria cases, and it was
stipulated that even confirmed negative cases were to
be administered ACT [5]. The goal of this blanket policy
was to reduce the risk of severe illness or death as a result
of malaria [6]. However, since 2010 the guidelines have
been updated to specify that prior to treatment, all cases
of suspected malaria should receive a malaria blood test,
and only patients testing positive for malaria should be
administered an ACT [7].
These policy changes have been complemented by
several private sector initiatives to ensure patients are
tested and treated according the national malaria treatment guidelines. Uganda’s current policy stipulates that
licensed private sector outlets are authorized to sell overthe-counter medicines including anti-malarials (and
ACT as of 2008) but not antibiotics or injections [8].
Diagnostic testing with rapid diagnostic tests (RDTs) is
only permitted in approved pilot areas of the country.
In 2010, Uganda participated in the Affordable Medicines Facility-malaria (AMFm) with the aim of increasing
uptake of quality-assured ACT (QAACT) and decreasing use of artemisinin monotherapies. The programme
was designed as a ‘factory-gate’ subsidy, reducing the
cost of ACT to public and private sector first-line buyers by roughly 95% [9]. Following the AMFm pilot phase
from 2010 to 2011, the programme of subsidies and
price negotiations continued as part of Uganda’s malaria
funding application to the Global Fund, and was called
the Private Sector Co-payment Mechanism (CPM) for
QAACT. Several supporting interventions in Uganda

planned for implementation for the subsidy programme
included behaviour change communications (BCC), the
training of private sector providers, and the introduction of recommended retail prices for QAACT; however,
there were challenges which prevented the BCC activities
from being implemented [10]. All subsidized QAACT
packaging carried a green leaf logo as an indication of
quality and affordable anti-malarial treatment. The Independent Evaluation of the AMFm concluded that overall
there was a significant increase in availability of QAACT
in the private sector following AMFm implementation,
from 11.3% in 2010 to 65.5% in 2011 [11].
Aside from the CPM, more recent examples of strategies to improve malaria case management services
include the introduction of malaria diagnostics into
licensed private outlets, typically drug shops [12–14].
These pilot interventions have included the provision of
subsidized RDTs and have been implemented with supportive interventions, including training and supervision
of providers. Several studies have concluded that RDTs
can be stocked and used safely to treat malaria outside
formal health facilities in Uganda [15, 16] and that their
use can lead to reduced prescription of anti-malarial
drugs among RDT negative patients [12, 13, 17]. Given
these positive findings, the policy on diagnostic testing in
the private sector is under review by the government.
The various private sector investments discussed
above have played an important role in improving private sector malaria case management readiness and
performance in Uganda. Contemporary malaria case
management market data on anti-malarials and malaria
diagnostics will provide an important benchmark of this
success. Since 2008, the ACTwatch project has been
implemented in Uganda to monitor anti-malarial and
diagnostic markets. To date, five national outlet surveys
have been implemented across the country. This paper
describes evidence from Uganda’s last survey round
implemented in 2015 and examines the role, readiness
and performance of private providers at a national level
in Uganda. It is complemented with a fever case management survey to explore the performance of private
sector and adherence to national guidelines by private providers. These data will be useful to inform and
improve strategies and policies for malaria case management in Uganda’s private sector.
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Methods
The ACTwatch national anti-malarial outlet survey was
conducted concurrently with the fever case management
study, but they differed in their design and sampling
approaches.
Outlet survey

The ACTwatch nationally representative anti-malarial
outlet survey was conducted in Uganda between May
18th 2015 and July 2nd 2015. A representative sample of
27 sub-counties was selected in urban (14) and rural (13)
domains with probability proportional to size. Within
selected clusters, a census of all outlets with the potential
to sell or distribute anti-malarials and/or provide malaria
blood testing was completed. In Uganda, these outlet
types included public health facilities, community health
workers (CHW), private not-for-profit health facilities,
private for-profit health facilities, pharmacies, and drug
stores. Additional sub-counties were selected for oversampling of public health facilities and pharmacies. This
booster sampling strategy was used to obtain a sufficient
sample size for indicator estimates within these important outlet types.
The outlet survey was powered to detect a minimum
of a 20% point change in availability of QAACT among
anti-malarial stocking outlets between each round and
within each domain at the 5% significance level with 80%
power. The number of survey clusters was calculated for
each research domain based on the required number of
anti-malarial stocking outlets and assumptions about
the number of anti-malarial stocking outlets per cluster.
Sample size requirements for the 2015 survey were calculated using information from the previous survey round
including anti-malarial and QAACT availability, outlet
density per cluster, and design effect.
To implement the census, interviewers moved systematically through each of the selected clusters, looking
for the aforementioned outlets. Where available, lists of
registered licensed outlets were used to help identify any
outlets. Snowball sampling was also used by interviewers
to make sure all potential outlets were identified during
the census process. Maps, illustrating local boundaries,
were also used to identify the administrative boundaries
of each cluster.
Outlets were screened to determine eligibility. Outlets
eligible for the survey met at least one of three criteria:
(1) one or more anti-malarials were in stock on the day of
the survey; (2) one or more anti-malarials were in stock
in the 3 months preceding the survey; and/or (3) malaria
blood testing (microscopy or RDT) was available.
Among outlets that met the criteria, the main questionnaire with a malaria and RDT audit sheet was
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administered to consenting providers. Providers were
asked to show the interviewer all anti-malarials currently available. A product audit sheet captured information for each unique anti-malarial product in the outlet,
including formulation, brand name, active ingredients
and strengths, package size, manufacturer and country of manufacture. Providers were asked to report the
retail and wholesale price for each medicine as well as the
amount distributed to individual consumers in the last
week.
Quality control measures implemented during data
collection included questionnaire review by supervisors
and interview verification visits conducted by quality
controllers among 10 and 20% of all outlets.
Fever case management study

The fever case management study employed a cross-sectional quantitative design, including observations of provider-patient interactions and patient exit interviews. Data
were collected between May 20th and August 3rd, 2015.
The fever case management study was implemented in
the private sector, among private for-profit health facilities, pharmacies and drug stores. Potential outlets were
identified during the main outlet survey and included
in this sub-sample if they had both the first-line treatment ACT [artemether–lumefantrine (AL)], in stock on
the day of survey as well as diagnostic testing available.
Observation and exit interviews were conducted within
a few days of completion for the the main outlet survey.
The target population for the fever case management
study included providers and patients, or their caregivers, seeking fever treatment. The inclusion criteria
were: patients (or their caregivers) with fever or history
of fever, seeking care at the outlet for this fever for the
first time; minimum 18 years of age (or 2 months of age
providing the caregiver was at least 18 years of age); not
currently pregnant; and not experiencing symptoms of
severe illness.
Among eligible outlets with consenting providers,
patients or their caregivers seeking treatment for fever
were sampled for inclusion in the study. All patients
meeting eligibility criteria as outlined above were invited
to participate in the study. A quota sampling approach
was used, with the aim of achieving two interviews per
outlet: one from a caregiver on behalf of a child under
the age of five and one from an adult/or the caregiver of
a patient over the age of five. Following informed consent procedures, a structured observation checklist was
completed by an interviewer observing the interactions
that the patient had with providers as she/he was provided with services at the outlet. The observation was
concerned primarily with provider behaviors, including
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the provider assessment of the patient, the administration of RDT and counseling for treatment with ACT. A
brief exit interview was completed with the patient when
he or she left the outlet. The exit interview was concerned with capturing information about all medicines
prescribed/obtained. The exit interview also assessed the
patient understanding of the test result(s) and medication regimens prescribed. Once the quota of two interviews per outlet was achieved, the interviewers moved
on to the next eligible outlet. A maximum of 1 day was
spent at the outlet by interviewers, and if the patient
quota was not met, the interviewers moved to the next
outlet.
Training

Interviewers, supervisors, and quality controllers
received training that included an orientation to the
study designs and questionnaires, classroom training on
completing observation and exit interviews, and a practice field exercise. Additional training was provided for
supervisors and quality-controllers focused on field monitoring, verification visits, and census procedures.
Protection of human subjects

Both the main outlet survey and the fever case management study were submitted for ethical review. The
application was reviewed and approved by the Makerere
University College of Health Sciences School of Medicine
Research Ethics Committee (REC REF No. 2008-057).
The PSI Research Ethics Board ceded review to the ethics committee in Uganda. Provider interviews, patient
consultation observation, and patient exit interviews
were completed only after administration of a standard
informed consent form and patient/provider consent to
participate in the study. Patients and providers had the
option to end the interview at any point during the study.
Standard measures were employed to maintain confidentiality and anonymity.
Data entry

Different approaches were used for the main outlet survey and the fever case management study. A structured
questionnaire programmed into mobile phones using
DroidDB software was used to complete an audit of all
anti-malarials and RDTs as well as a provider interview
for the main outlet survey. Paper questionnaires were
used to collect data for the fever case management study.
A Microsoft Access (©Microsoft, Redmond, WA) database was developed and used to conduct double data
entry from fever case management questionnaires. Verification records from data entry and supervisor monitoring sheets were reviewed and used to confirm complete
data entry.
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Analysis

Stata 13.1 (©StataCorp, College Station, TX) was used to
clean and analyse data from the outlet survey and fever
case management study. Sampling weights were applied
to account for variations in probability of selection and
standard error estimation accounted for clustering at
the sub-district level for the outlet survey. All point estimates were weighted using survey settings and all standard errors calculated taking account of the clustered and
stratified sampling strategy with the relevant suite of survey commands.
For the outlet survey, standard indicators were constructed according to definitions applied across the
ACTwatch project and have been described in detail
elsewhere [18, 19]. Briefly, anti-malarials identified during the outlet drug audit were classified according to
information on drug formulation, active ingredients
and strengths as non-artemisinin therapies, artemisinin
monotherapies and ACT. Non-artemisinin therapies
were classified as sulfadoxine–pyrimethamine (SP), or
other non-artemisinin therapies. Artemisinin monotherapies were further classified as oral and non-oral, the
latter including medicines recommended for the firstline treatment of severe malaria. ACT were classified
as QAACT or non QAACT. QAACT were either ACT
products granted World Health Organization (WHO)
prequalification, those granted regulatory approval by
the European Medicines Agency (EMA) or those in compliance with the Global Fund Quality Assurance Policy.
Classification was completed by matching product audit
information (formulation, active ingredients, strengths,
manufacturer, country of manufacturer and package size)
to the most recent lists of approved medicines available
from the WHO, EMA and Global Fund.
Anti-malarial availability and malaria diagnostic availability is presented out of all screened outlets in the private sector and by outlet type.
To calculate market share, anti-malarial sales were
standardized to allow meaningful comparisons between
anti-malarials with different treatment courses and different formulations. The adult equivalent treatment dose
(AETD) was defined as the amount of active ingredient
required to treat an adult weighing 60 kg according to
WHO treatment guidelines [7]. Provider reports on the
amount of the drug sold or distributed during the week
preceding the survey were used to calculate volumes in
AETDs according to type of anti-malarial. Measures of
volume include all dosage forms to provide a complete
assessment of anti-malarial market share. Market share is
presented within the private sector and within each private sector outlet type.
Price data presented were collected in Ugandan shilling and converted to United States dollars using local
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Public Health Facility
Community Health Worker
Private Not For Profit Facility
Private For Profit Facility
Pharmacy
Drug Store

Fig. 1 Anti-malarial market share

PERCENT ANTI-MALARIAL MARKET SHARE

exchange rates for the period of data collection. The
price of QAACT was presented as the price of prepackaged therapy for a 60 kg adult (i.e. AL 20/120, package size of 24 tablets), and the price of pre-packaged
therapy for a 10 kg child (i.e. AL 20/120 package size of
6 tablets). Median private sector price per AETD was
also calculated for QAACT and for the most popular
non-artemisinin therapy in the most recent round, SP.
The interquartile range (IQR) is presented as a measure
of dispersion. While all QAACT are by definition tablet formulations, SP may be available in other formulations including syrups and injections. Price measures for
QAACT, SP, adult QA AL and child QA AL included tablet anti-malarials only, given differences in unit costs for
tablet and non-tablet formulations. Price was also calculated for an ampule of quinine and artemether injection,
and presented separately.
The private sector price of a malaria test using microscopy or RDT was assessed through provider reports of

100%

consumer prices. Providers were asked to report the
total cost of testing to a customer including any consultation or service fees. Median private sector price for
microscopy or RDTs was calculated and reported with
the IQR as a measure of dispersion.
The fever case management indicators include
respondents that completed both the observation
and exit interview components. Indicators include a
description of the sample, including whether or not the
febrile patient was present at the consultation and if the
respondent had sought treatment elsewhere. Point estimates were also calculated to present data on whether
or not the respondent received a test, the type of test
received, and the result of the test (tested positive, tested
negative, not tested). The types of medicines received
were classified according to anti-malarials as well as
antipyretics, and antibiotics.

Results
Outlet survey

A total of 9438 outlets were screened for availability of
anti-malarials and/or malaria blood testing services.
Of screened outlets, 4598 were stocking anti-malarials
or testing on the day of the survey or within the past
3 months, and 4724 were subsequently interviewed
(Additional file 1: Table S1).
Anti‑malarial market share

Figure 1 illustrates the market share of anti-malarials
distributed according to different outlet types and by
sector. The majority of the anti-malarials were distributed through the private sector (54.3%), with third of all
anti-malarials distributed through drug stores (31.4%),
followed by private for-profit health facilities (14.1%)
and pharmacies (8.8%). In comparison, 45.7% of the antimalarial market share was distributed through the public sector, with most anti-malarials being administered
through public health facilities (40.0%).

90%
80%

Anti‑malarial market share within the private sector

70%

Figure 2 illustrates the market share of different classes
of anti-malarials distributed within the private outlets
and for the total private sector. Across the private sector, ACT was the most commonly distributed type of
anti-malarial (66.1%) and most commonly QAACT
(47.5%). Most of the QAACT market share was found
in drug stores (52.9%), followed by private for-profit
health facilities (41.5%) and pharmacies (38.0%).
Across the private sector, SP comprised 21.3% of the
anti-malarial market share. No oral artemisinin monotherapy products were found. Non-oral artemisinin
therapy made up 1.7% of the overall private market
share.

60%
50%
40%
30%
20%
10%
0%

Private for-profit
facility

Pharmacy

QAACT with the green leaf logo
Non-QAACT
Oral quinine
Oral artemisinin monotherapy

Drug store

Total private

QAACT without the green leaf logo
SP
Other non-artemisinin therapy
Non-oral artemisinin monotherapy

Fig. 2 Anti-malarial market share within the private sector
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Table 1 Availability of malaria testing and anti-malarials, among all screened private sector outlets
Availability among all outlets

Private for-profit health
facility

Pharmacy

Drug store

Total private sector

N = 1023
% (CI)

N = 493
% (CI)

N = 1967
% (CI)

N = 3483
% (CI)

Anti-malarials
Any anti-malarial

93.1 (90.4, 95.1)

98.3 (96.4, 99.2)

93.4 (91.3, 95.0)

93.4 (91.8, 94.7)

Any ACT

80.3 (74.2, 85.3)

97.9 (96.1, 98.9)

80.4 (76.9, 83.5)

80.7 (77.3, 83.6)

Any QAACT

69.5 (63.2, 75.1)

94.8 (91.6, 96.8)

72.3 (68.2, 76.0)

72.0 (68.2, 75.4)

SP

48.5 (42.1, 54.8)

82.5 (76.3, 87.3)

45.9 (40.3, 51.7)

47.1 (42.1, 52.1)

Oral quinine

65.9 (60.7, 70.8)

94.1 (89.1, 96.8)

75.0 (70.8, 78.9)

73.2 (69.5, 76.6)

9.1 (6.2, 13.2)

53.5 (43.1, 63.6)

10.5 (8.4, 13.1)

10.8 (9.1, 12.8)

Injectable quinine

67.1 (60.2, 73.4)

79.5 (70.1, 86.5)

20.0 (16.5, 24.0)

31.9 (28.5, 35.6)

Non oral artemisinin monotherapy

47.7 (42.2, 53.3)

84.0 (77.0, 89.2)

10.9 (8.2, 14.4)

20.6 (17.5, 24.1)

Other non-artemisinin therapya

Malaria diagnostic testing
Any diagnostic

70.6 (63.6, 76.7)

51.4 (44.1, 58.6)

20.9 (17.8, 24.4)

32.9 (29.4, 36.5)

RDT

47.4 (41.4, 53.4)

51.4 (44.1, 58.6)

20.1 (17.1, 23.4)

26.8 (23.9, 30.0)

Microscopy

42.0 (35.1, 49.1)

0.6 (0.2, 1.4)

1.2 (0.6, 2.3)

10.6 (8.5, 13.2)

49.0 (41.9, 56.1)

16.1 (13.6, 19.0)

25.1 (22.2, 28.4)

Readiness for malaria case management (ACT and malaria testing)
Quality assured ACT and testing
a

52.5 (46.2, 58.6)

Other non-artemisinin therapy included: amodiaquine, atovaquone-proguanil, chloroquine, hydroxychloroquine sulphate, mefloquine, primaquine

Table 2 Median private sector price of malaria testing and anti-malarials
Private for-profit facility

Pharmacy

Drug store

Private sector total

Median [IQR](N of products)

Median [IQR](N of products)

Median [IQR](N of products)

Median [IQR](N of products)

$1.29 [0.97–1.62] (670)

$1.62 [1.29–1.62] (1269)

$1.62 [1.29–1.94] (2603)

Median price of a package of
Adult QA AL
Pediatric QA AL

$1.62 [1.29–2.26] (664)
$0.65 [0.32–0.97]

(84)

$0.48 [0.32–0.97]

(134)

$0.32 [0.29–0.48]

(173)

$0.39 [0.32–0.58] (391)

Median price of tablet AETD
QAACT
SP

$1.94 [1.29–3.23] (1365)
$0.65 [0.48–0.81]

(605)

$1.28 [$0.97–$1.94] (1467)
$0.48 [0.48–0.65]

(587)

$1.55 [$0.97–$1.94] (2446)
$0.48 [0.48–0.65]

(1122)

$1.62 [$1.13–$1.94] (4811)
$0.48 [0.48–0.65] (2314)

Median price of an ampoule
Quinine injection
Artemether injection

$0.81 [0.48–1.13] (691)

$0.48 [0.32–0.81] (453)

$0.81 [0.32–0.65] (307)

$0.97 [0.48–0.97] (1451)

(455)

(393)

(162)

$0.97 [0.65–1.29] (1010)

$0.97 [0.81–1.62]

$0.54 [0.39–0.65]

$0.81 [0.48–0.97]

Median price of a microscopy
Adult

$0.97 [0.65–0.97] (409)

$1.62 [0.97–1.62] (8)

$0.65 [0.48–0.97] (19)

$0.97 [0.65–0.97] (436)

Child under age five

$0.97 [0.65–0.97] (410)

$1.62 [0.97–1.62] (8)

$0.65 [0.48–0.97] (18)

$0.81 [0.65–0.97] (436)

Adult

$0.97 [0.65–0.97] (513)

$0.97 [0.32–0.97] (44)

$0.65 [0.65–0.97] (390)

$0.81 [0.65–0.97] (947)

Child under five

$0.97 [0.65–0.97] (514)

$0.97 [0.32–0.97] (44)

$0.65 [0.65–0.97] (391)

$0.81 [0.65–0.97] (949)

Median price of RDT

Availability of anti‑malarials and testing

Table 1 illustrates availability of anti-malarials and
malaria diagnostic tests among all screened private sector
outlets. Among all screened outlets, 93.4% had an antimalarial in stock on the day of survey. ACT was stocked
in 80.7% of the private sector; availability of QAACT was
72.0%. Oral quinine was the most commonly available
non-artemisinin therapy (73.2%), followed by SP (47.1%).

Malaria blood testing was available in 32.9% of private sector outlets, and highest among private forprofit facilities (70.6%) followed by pharmacies (51.4%)
and drug stores (20.9%). Availability of parasitological
testing was mainly attributed to RDT, with the exception of private for-profit facilities where both microscopy (42.0%) and RDT (47.4%) were available at similar
levels.
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Table 3 Description of fever patients, by outlet type
Private for-profit
health facility

Pharmacy

Drug store

All private sector
outlets

N = 630

N = 219

N = 424

N = 1273

Respondent is the patient and present at the outlet/consultation

85.4 (79.5–89.9)

49.4 (36.5–62.3)

65.3 (58.9–71.2)

74.2 (69.5–78.4)

23.1 (19.7–27.0)

Prior to the current visit, the percent of all respondents that:
Sought treatment from another source

20.8 (16.7–25.7)

37.6 (28.8–47.2)

24.4 (19.3–30.4)

Sought treatment from a public sector source

5.9 (3.6–9.4)

18.0 (12.7–25.0)

12.8 (8.9–17.9)

9.7 (7.4–12.6)

Sought treatment from a private sector source

14.9 (11.3–19.3)

19.9 (9.8–36.3)

15.6 (10.3–22.8)

13.8 (10.7–17.7)

Received a malaria blood test from a previous treatment
source

6.5 (4.3–9.8)

25.5 (17.3–35.9)

8.5 (5.1–14.0)

8.6 (7.0–10.5)

Received any medicine from a previous treatment source

19.6 (15.6–24.4)

16.7 (10.1–26.4)

22.8 (16.8–30.0)

20.5 (16.8–24.6)

Received an anti-malarial from a previous treatment source

12.4 (9.0–16.8)

7.1 (3.3–14.6)

13.0 (9.8–17.2)

12.5 (9.9–15.8)

ACT and malaria testing was available 25.1% of all private sector outlets. This was highest among private forprofit facilities (52.5%), followed by pharmacies (49.0%)
and drug stores (16.1%).
Price of malaria testing and anti‑malarials

In the private sector, the median retail price of a package of adult QA AL was four times more expensive than
pediatric QA AL ($1.62 and $0.39 respectively). An
AETD of QAACT was also three times more expensive than an AETD of SP ($1.62 and $0.48 respectively)
(Table 2). Anti-malarials were typically less expensive in
pharmacies and drug stores as compared to private forprofit facilities.

Private for-Profit Health Facilities

N=630

The median retail price for an adult microscopy and
RDT was $0.97 and $0.81, respectively. The retail price of
an adult and child RDT was $0.81. Malaria diagnosis was
least expensive in drug stores compared to other private
sector outlet types and the price did not differ by type of
test ($0.65).
Fever case management results

A total of 1266 outlets were identified during the national
outlet survey that met the fever case management survey
eligibility criteria. Of these eligible outlets, 1146 outlets
were visited for the fever case management study. There
were 1089 outlets that participated in patient screening
and 259 outlets that did not have any eligible patients. Of

Pharmacies

Drug Stores

N=219

N=424

All Private Sector Outlet Types

Received a RDT

Present, did not receive a malaria test

Received a RDT and malaria microscopy

Not present (did not receive a malaria test)

Received malaria microscopy
Fig. 3 Percentage of respondents who received a malaria blood test, across outlet type

N = 1,273
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Table 4 Fever treatment by malaria test result across all private outlets
Malaria test positive
% (95% CI)
N = 266

Malaria test negative
% (95% CI)
N = 250

Not tested
% (95% CI)
N = 753

Any anti-malarial

83.0 (74.6–89.0)

14.3 (9.3–21.2)

50.8 (44.4–57.3)

Any ACT

60.0 (53.3–66.3)

10.2 (6.5–15.5)

42.7 (36.4–49.3)

QA ACT

48.5 (41.3–55.7)

6.6 (3.7–11.6)

33.9 (27.7–40.7)

Non-quality assured ACT

12.2 (8.1–18.1)

3.5 (1.3–9.4)

8.9 (5.6–13.7)

Non-artemisinin therapya

14.4 (9.6–21.1)

3.6 (1.3–9.3)

8.4 (5.9–11.8)

Artemisinin monotherapyb

14.9 (9.3–23.0)

0.5 (0.1–3.6)

1.1 (0.4–3.3)

Antibiotic

42.5 (34.1–51.3)

54.7 (45.7–63.4)

24.1 (18.9–30.1)

Antipyretic

78.7 (71.4–84.5)

61.2 (50.6–70.9)

64.9 (59.5–70.0)

0.2 (0.1, 0.8)

3.3 (0.7, 14.4)

0.2 (<0.1, 1.8)

Patient received a prescription for an anti-malarial, but did not
receive an anti-malarial at the outlet (exiting without treatment)
a

Primarily quinine injections, tablets, syrups as well as SP tablets and a few chloroquine tablet anti-malarials

b

Primarily artemether injections

a total of 830 outlets with complete patient observation
and exit interviews, 423 were private for-profit health
facilities, 147 were pharmacies and 260 were drug stores.
A total of 9330 patients were screened during the
fever case management study. Of these patients, 1273
had complete patient observations and exit interviews.
The age of the patient observations and exit interviews
ranged from 0 years to over 50 years: 545 patients were
between 0 and 4 years; 170 patients were between 5 and
14 years; 503 patients were between 15 and 49 years and
49 patients were over 50 years of age (age data were missing for 6 respondents).
Fever case management study sample description

Table 3 provides a description of fever patients who
were eligible for the fever case management study and
had completed both observation and exit interviews.
The results show that across the private sector, 74.2% of
respondents were patients seeking treatment at outlets
as compared to 25.8% of respondents that were seeking
treatment on behalf of the patient. 23.1% of respondents
had sought treatment elsewhere prior to being interviewed at the facility and this first source of treatment
was most commonly from other private facilities (13.8%)
rather than the public sector (9.7%). Among all respondents, 8.6% reported receiving a malaria test, 20.5%
received a medicine, and 12.5% an anti-malarial at a previous treatment source.
Malaria blood testing

Figure 3 shows the relative distribution of respondents
at the outlet according to whether or not they received a
malaria diagnostic test, for the private sector and by outlet type. Almost half of all respondents received a malaria
test (44.4%), and the most common type of test received

was RDT (28.8%). Malaria testing was most common
among private for-profit facilities (63.0%), followed by
drug stores (29.0%). In 48.5% of pharmacies and 35.6%
of drug stores, respondents were patients present at the
outlet and did not receive a test.
Fever treatment by malaria test results

Table 4 illustrates the treatment outcome by malaria
test result. Among respondents who tested positive for
malaria, 83.0% received an anti-malarial, 60.0% received
ACT and 48.5% received QAACT. QAACT was most
commonly administered to confirmed positive patients
at drug stores (68.4%) (Additional file 2: Table S2). 14.4%
of confirmed positive patients received non-artemisinin
therapy, mainly quinine injections, tablets or syrups, SP
tablets or chloroquine tablets, or an artemisinin monotherapy, which primarily consisted of artemether injections (14.9%). Furthermore, 78.7% of all patients with
a positive malaria test received an antipyretic (78.7%),
while 42.5% received an antibiotic.
Among patients testing negative for malaria, 14.3%
were administered an anti-malarial, 10.2% received an
ACT, and 3.6% a non-artemisinin therapy. Over half
received an antibiotic (54.7%) and 61.2% received an antipyretic (Table 4).
Among patients who were not tested for malaria, 50.8%
were treated with an anti-malarial, 42.7% were treated
with ACT and 33.9% QAACT, and 8.4% were given a
non-artemisinin therapy. 24.1% were treated with an
antibiotic and 64.9% were given an antipyretic (Table 4).

Discussion
The private sector in Uganda was responsible for most
of the anti-malarial distribution, with more than half of
anti-malarials administered through this sector in 2015.
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This is concurrent with other research that most patients
seek treatment from the private sector in Uganda [20–
23]. Most of the anti-malarials distributed by the private
sector were ACT, though one in five anti-malarials distributed were SP, which was notably less expensive than
ACT. While in many cases, private providers use available
malaria commodities to test fever cases and treat according to test results, gaps exist in appropriate case management. Findings point to recommendations for improving
coverage of appropriate malaria case management.
Role of the private sector in malaria case management

Most of the private sector anti-malarial distribution
was through drug stores, comprising one third of the
anti-malarial market share followed by private for-profit
facilities and pharmacies. Outlets that have been found
to play an important role in anti-malarial distribution
in other countries such as general retailers and itinerant
drug vendors do not provide anti-malarials in Uganda,
as evidenced by multiple ACTwatch survey rounds [20,
21]. For example, in 2013, 1241 general retailers were
screened for anti-malarials and none were found to be
stocking these medicines [21].
Given the importance of drug stores in malaria case
management in Uganda, what is known about them?
They are authorized to sell over-the-counter medicines
and should be licensed by the National Drug Authority. National regulations stipulate that they should be
staffed by qualified health providers and administration
of medicines should follow national policies. However,
in practice it is possible that a substantial proportion of
these outlets are not registered [3, 24]. For example, a
census of private outlets in three rural eastern districts
of Uganda estimated that up to 77.1% of private vendors
may be unlicensed [25]. These unlicensed drug stores are
described as operating illegally and manned by unqualified staff selling a range of prescription and non-prescription medicines [3]. The presence of these unlicensed drug
stores may be particularly common given evidence that
the implementation of laws and regulations governing
medical practice can be challenging [26].
Strategies to license drugs stores may help to regulate
these outlets and allow them to be included as part of the
formal health care system. Such efforts may be an important means to improve access to quality malaria case
management services. Several strategies in other countries have demonstrated that unlicensed providers have
been successfully integrated into the formal health system through training, supervision, business incentives,
and accreditation [27]. However, systematic evaluations
of these activities have rarely been conducted [28]. While
allowing unlicensed drug shops to participate in future
programmes may expand the reach of case management
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services, these should be aligned in the context of Uganda’s national policy and regulatory framework.
Private sector readiness for appropriate malaria case
management

Overall, there was high availability of ACT in the private sector (80.7%). The findings illustrate there was high
readiness to administer ACT in the private sector, reflecting increasing availability of ACT over time in Uganda, as
evidenced by data from previous outlet surveys [20, 21,
29]. For example, among drug shops surveyed, the percentage of outlets stocking an ACT medicine increased
over time from 12.9% in 2009, to 63.5% in 2011 and to
75.1% in 2013. These findings reflect private sector initiatives in Uganda, including the AMFm and CPM, where
in 2015, 8.48 million ACT doses had been delivered to
private sector First Line Buyers, albeit at reduced levels
since a peak of 19.4 million treatment doses in 2013 (personal communication, Global Fund).
While many private sector outlets have QAACT available following on initiatives to improve private sector availability, only a quarter have both QAACT and
malaria blood testing available. Access to diagnostic testing has remained low in the private sector, though previous ACTwatch national surveys in Uganda have generally
reported an increase over the past decade [20, 21, 29].
In particular, testing availability was moderate to high
in pharmacies and private for-profit facilities, but particularly low among drug stores. The findings also reflect
population-based studies which have found that less than
15% of febrile children under five received a malaria diagnostic test from the private sector in Uganda [18].
Low private sector availability of malaria blood testing
can be partly explained by the national regulatory framework which has only permitted the use of RDT among
licensed private drug stores in pilot settings. However,
the results from a pilot findings in Uganda are promising and suggest that these outlets can safely and correctly
test for malaria with appropriate training, supervision,
and record keeping [30, 31]. For example, RDT-positive
patients were 5.6% points more likely to buy ACT and
31.4% points more likely to buy other anti-malarials than
those not tested at all [32]. While this suggests that a
policy in favor of parasitological testing in licensed drug
stores may foster increased access and appropriate case
management of suspected malaria cases, scaling this
up at a national level is not without its challenges. The
experience of introducing RDT in the private sector in
Cambodia over the last 10 years has shown challenges
with RDT supply, as well as determining effective incentives for private providers and patients to use these tests
and adhere to their results [33]. In addition, other studies have shown that RDT may result in an increase in
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prescription rates for antibiotics when RDTs were introduced, particularly in RDT negative cases [34, 35]. This
suggests that the introduction of RDTs may also have
inadvertent effects on the use of other medicines.
Private sector anti‑malarial distribution

More than half of the anti-malarials distributed in the
private sector were ACT (66.1%), and in 2015 ACT with
the green leaf logo comprised 43.6% of the market share.
Non-artemisinin therapy comprised one-fifth of the
market share, with SP most commonly sold/distributed.
While there were few differences between outlet types,
QAACT market share was highest among drug stores.
The 2015 findings speak to positive improvements in
the private sector market share since the implementation
of the AMFm program, even while deliveries of ACT with
the green leaf logo have been declining since 2013 as funding of co-paid ACT dropped in 2014 and 2015. In 2010,
market share for any ACT in Uganda’s private sector was
estimated at 5.1% and this increased to 38.5% in 2011. The
findings from the most recent survey, reported here, illustrate a further 27.6% point increase of ACT market share.
With most of this increase attributed to ACT with the
green leaf, this suggests that positive improvements can
be associated with the CPM ACT subsidy programme.
Despite widespread distribution of ACT, non-artemisinin therapies continued to be widely available in
the private sector and there was still some distribution
of these medicines, notably quinine and SP. Findings
from the fever case management study also indicate that
artemether injections were being administered for confirmed, uncomplicated malaria cases, despite outlets having ACT in stock. While SP should continue to account
for a portion of anti-malarial market share because
this product is recommended for intermittent preventive treatment in pregnancy (IPTp) [3], the substantial
SP market share is cause for concern, and suggests it is
being administered for malaria case management, against
national (and international) guidelines. This is also supported by other evidence that suggests many of the SP
products have packaging and patient instructions indicating its use for uncomplicated malaria for all ages [36].
One reason for the widespread availability and distribution of non-artemisinin therapy may be related to price.
The findings from the outlet survey show that QAACT
was three times more expensive than SP. QAACT was
also more expensive than artemether injection fever
case management study. These price barriers could have
driven patient demand and the decision by the provider
to administer a less expensive treatment option rather
than QAACT. In 2010, one of the AMFm supportive
interventions included a recommended retail price (RRP)
for QAACT, which was $0.47 for an adult dose and $0.12
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for a child dose, however consumer awareness raising
activities had not yet been implemented by 2015. The
results from this study demonstrate that the median price
for an adult and child treatment was three times higher
than the RRP, at $1.62 and $0.39 respectively. ACT retail
prices therefore may not be low enough to achieve optimal uptake, pointing to the need for a further reduction in ACT retail price [6, 11]. Implementation of the
planned BCC should be a useful strategy to increase
awareness of the recommended retail price for QAACT,
and promote demand for this treatment at an affordable
price. Such activities could be coupled with a strengthening policies and regulations to curtail the availability and
distribution of non-artemisinin therapies for malaria case
management in the private sector [37].
Confirmatory testing in the private sector

The fever case management findings point to sub-optimal private sector case management, illustrating that
even in situations where malaria diagnostic testing is
available, patients are not routinely tested. The findings
demonstrate that among all respondents interviewed,
less than half (44%) received a confirmatory test and this
was even lower among those visiting drug stores (29%),
where most treatment is sought. These findings however
are also consistent with other research that has shown
irrational treatment decisions by health providers despite
availability of diagnostic tests [38–40].
The findings from the fever case management study
highlight some of the complexities of malaria diagnosis.
For example, one in four of the respondents interviewed
were seeking treatment on behalf of someone else who
was not present and therefore could not be tested. The
findings also illustrate how the patient may have already
been managed at a different facility—almost one in four
respondents had sought treatment elsewhere prior to
attending the outlet where they were interviewed. Similarly, a proportion at the consultation had already been
given an anti-malarial at a different facility.
Several other barriers to administering malaria confirmatory testing in the private sector have been documented. This includes whether or not private providers
will have an economic incentive to promote and sell
RDTs to patients considering the revenue that is generated from anti-malarials [32, 41]. There may also be concern over what to do when a result from a test is negative
[33]. From the patient’s perspective, there may also be a
financial disincentive to purchase both a test and a medicine. This study found that the price of a malaria test was
less than the price of treatment with an ACT for adults.
However for children, there was no financial incentive to test before treatment because ACT treatment
was cheaper than RDT testing. Although there was an
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apparent financial incentive to test before treatment with
an ACT for adults, the price of testing was still higher
than other available non-artemisinin therapies including the popular option, SP. Furthermore, patients seeking
malaria treatment may see the price of an RDT test on
top of the price they must pay for treatment as an unnecessary cost. In fact, data from a previous study in Uganda
illustrated that drug shop customers’ willingness-to-pay
threshold for RDTs was considerably lower than the
actual RDT price, with many preferring to spend their
money on medicines rather than testing [42]. Thus, provider motivation and additional cost to patients for testing remain important challenges to scaling-up diagnostic
testing within the private sector.
Several strategies may be useful to overcome these
barriers. One important strategy will be to build consumer demand for testing. The findings from the fever
case management study show that testing was available
in private sector outlets, yet fewer than half of patients
received a confirmatory test. Social and behavior change
communication that targets patients and provides them
with information and education on the importance of
confirmatory testing, will be an important means to
increase demand for testing. Demand side strategies
could also be supported with several supply side interventions to ensure RDTs are affordable and accessible to
patients. This may include bundling RDTs and ACT as a
single commodity rather than two separate commodities
[42], such that if the RDT was positive the patient could
then be offered a free or highly subsided ACT. A voucher
system for RDTs and ACT may be another fruitful avenue
to consider, where a full refund of the RDT is offered for
positive patients on the condition that they purchase an
ACT [14]. Such private sector supply side strategies could
be complemented with aforementioned patient-targeted
BCC that promotes RDTs as a necessary and affordable
commodity [3]. Of promise is that several strategies have
demonstrated successful introduction of RDTs in Uganda’s private sector [12, 13, 43]. Lessons from these studies can pave the way for future scale-up of confirmatory
testing and can consider these several options to promote
diagnostic testing among all patients.
Treatment according to test results in the private sector

The findings from the fever case management study show
that among private sector outlets that had ACT and diagnostic services available, over 80% of patients who tested
positive for malaria received an anti-malarial. While
these results are promising, there is still a gap given
that one in five patients did not receive an anti-malarial,
despite a confirmed positive blood test. It is not clear
from the results of this study why these confirmed positive cases did not receive appropriate treatment as these
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outlets were all stocking ACTs. This could be related to
price or patient demand for certain treatments, and/
or that patients may have had other options for obtaining treatment elsewhere or at home. While anti-malarial
treatment was high among confirmed cases, treatment
with an ACT was lower at 60%, highlighting the problem
of availability and administration of non-ACTs for treatment of uncomplicated malaria.
The results also illustrate that within the private sector, that patients who are not tested commonly receive
treatment with an antipyretic. Treating fever with an
antipyretic is appropriate, but patients presenting with
fever and are not being tested are a missed opportunity
to catch what may be malaria infection and treat it appropriately. Furthermore, half of people not tested were
treated with an anti-malarial and confirmatory testing
prior to treatment could reduce what may be irrational
anti-malarial use.
Administration of an antibiotic was quite high among
those with a positive test result (42.5%) and many patients
also purchased several medicines, including antipyretics.
These findings are consistent with other studies implemented in Uganda’s private sector, which have found
widespread administration of antibiotics and antipyretics
among RDT positive patients [13].
Several studies have suggested that while there is a
reduction in anti-malarial treatment after RDT introduction [5–8], anti-malarials are administered despite negative test results. Findings from this study are promising
given that anti-malarial and specifically ACT prescription among malaria negative patients was low, and lower
than what has been observed in other studies [9–12].
There may be several reasons as to why anti-malarials are
still administered despite a negative test result, including
concerns of patient safety [44], a mistrust of negative test
results [45], or uncertainty as to what to do when faced
with a negative result [46].
One way to encourage providers to administer RDT
and adhere to test results may include increasing product awareness, both among patients to drive demand, but
also for providers to stock and sell RDT. This may require
intense BCC activities, as well as provider training. The
complexity of messaging is also noted as a key challenge,
given there is more than one message and one objective
[33]. It has been suggested that messaging should promote the need to be tested prior to treatment, to take a
recommended first-line treatment, and if test results are
negative to urge the patient not to take an anti-malarial.
A key challenge remaining for providers is what to do
if the patient tests negative. Simple algorithms may be
helpful, but additional provider training and support, as
well as a network of referral systems will be necessary to
address these obstacles.
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Limitations
The sample for the fever case management study was
dependent upon the findings from the concurrently
implemented ACTwatch outlet survey, which has previously documented limitations [19, 47]. In the fever case
management study, the outlets were identified through
the outlet survey census, and only those outlets with
ACT and diagnostics were included. Due to the small
time lag between the outlet survey and the fever case
management study, some previously eligible facilities
may have lost eligibility after having stock-outs of either
ACT or RDTs. Furthermore, there are notable challenges
with observational studies, particularly where multiple
data-collecting observers are used as was in the case
of this study. It is possible that the observers may have
differed in the consistent identification, discrimination
and recording of data. It is also likely that social desirability biases may have played a role in affecting provider behavior. The presence of fieldworkers observing
provider practices may have led to some change in their
behaviour.
Conclusion
The private sector is a common source of anti-malarial
treatment for people in Uganda. While many private
sector outlets have QAACT available following on from
initiatives to improve private sector availability, only onequarter have both QAACT and testing available. Results
show that in many instances, private providers who
stock ACT and malaria blood testing often use available
commodities to appropriately manage patients. However, gaps persist in ensuring all fever patients receive a
confirmatory test and QAACT. There is need to further
promote confirmatory testing and ACT among patients
and private sector providers, as well as discourage the
use of non-artemisinin therapies and inappropriate use
of injectable artemisinin monotherapies for cases of
uncomplicated malaria.
Additional files
Additional file 1. Detailed outlet survey sample description.
Additional file 2. Fever treatment by malaria test result and outlet type.
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